Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/21/2016
Arizona Clinical Research Center
mi
from
Tucson, AZ
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/21/2016
Arizona Clinical Research Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/21/2016
Associates in Oncology and Hematology
mi
from
Rockville, MD
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/21/2016
Associates in Oncology and Hematology
mi
from
Rockville, MD
Click here to add this to my saved trials
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/21/2016
Baylor Charles A. Sammons Cancer Center at Dallas
mi
from
Dallas, TX
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/21/2016
Baylor Charles A. Sammons Cancer Center at Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/21/2016
Charleston Hematology/Oncology Associates, Pa
mi
from
Charleston, SC
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/21/2016
Charleston Hematology/Oncology Associates, Pa
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/21/2016
Clearview Cancer Institute
mi
from
Huntsville, AL
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/21/2016
Clearview Cancer Institute
mi
from
Huntsville, AL
Click here to add this to my saved trials
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/21/2016
Mount Sinai Hospital
mi
from
New York, NY
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/21/2016
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/21/2016
NYU Cancer Center
mi
from
New York, NY
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/21/2016
NYU Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/21/2016
The Jones Clinic, PC
mi
from
Germantown, TN
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/21/2016
The Jones Clinic, PC
mi
from
Germantown, TN
Click here to add this to my saved trials
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/21/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/21/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/21/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/21/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/21/2016
City of Hope
mi
from
Duarte, CA
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/21/2016
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/21/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/21/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/21/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/21/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  5/5/2016
RMCC
mi
from
Denver, CO
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 5/5/2016
RMCC
mi
from
Denver, CO
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  5/5/2016
Emory
mi
from
Atlanta, GA
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 5/5/2016
Emory
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  5/5/2016
Rush
mi
from
Chicago, IL
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 5/5/2016
Rush
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  5/5/2016
IU
mi
from
Indianapolis, IN
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 5/5/2016
IU
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  5/5/2016
HUMC
mi
from
Hackensack, NJ
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 5/5/2016
HUMC
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  5/5/2016
Cornell
mi
from
New York City, NY
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 5/5/2016
Cornell
mi
from
New York City, NY
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  5/5/2016
OSU
mi
from
Columbus, OH
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 5/5/2016
OSU
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  5/5/2016
SCRI
mi
from
Nashville, TN
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 5/5/2016
SCRI
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  5/5/2016
MDACC
mi
from
Houston, TX
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 5/5/2016
MDACC
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status: Enrolling
Updated:  5/5/2016
GRU
mi
from
Augusta, GA
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status: Enrolling
Updated: 5/5/2016
GRU
mi
from
Augusta, GA
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status: Enrolling
Updated:  5/5/2016
DFCI
mi
from
Boston, MA
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status: Enrolling
Updated: 5/5/2016
DFCI
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status: Enrolling
Updated:  5/5/2016
OSU
mi
from
Columbus, OH
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status: Enrolling
Updated: 5/5/2016
OSU
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status: Enrolling
Updated:  5/5/2016
SCRI
mi
from
Nashville, TN
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status: Enrolling
Updated: 5/5/2016
SCRI
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status: Enrolling
Updated:  5/5/2016
MDACC
mi
from
Houston, TX
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status: Enrolling
Updated: 5/5/2016
MDACC
mi
from
Houston, TX
Click here to add this to my saved trials
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
Ponatinib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase
Status: Enrolling
Updated:  5/13/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
Ponatinib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase
Status: Enrolling
Updated: 5/13/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia
SCOR in Targeted Therapies for Infant Leukemia Project 3: Targeting FLT3 in Infant Leukemia
Status: Enrolling
Updated:  5/17/2016
Children's Oncology Group
mi
from
Monrovia, CA
Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia
SCOR in Targeted Therapies for Infant Leukemia Project 3: Targeting FLT3 in Infant Leukemia
Status: Enrolling
Updated: 5/17/2016
Children's Oncology Group
mi
from
Monrovia, CA
Click here to add this to my saved trials
Studying Biomarkers as a Diagnostic Tool in Samples From Younger Patients With B-Cell Acute Lymphoblastic Leukemia
OBSERVATIONAL: Replication Profiling as a Diagnostic Tool in B-cell Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  5/17/2016
Children's Oncology Group
mi
from
Monrovia, CA
Studying Biomarkers as a Diagnostic Tool in Samples From Younger Patients With B-Cell Acute Lymphoblastic Leukemia
OBSERVATIONAL: Replication Profiling as a Diagnostic Tool in B-cell Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 5/17/2016
Children's Oncology Group
mi
from
Monrovia, CA
Click here to add this to my saved trials
Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia
Observational - NUP98/JARID1A as a Recurrent Aberration in Pediatric Acute Megakaryoblastic Leukemia
Status: Enrolling
Updated:  5/17/2016
Children's Oncology Group
mi
from
Monrovia, CA
Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia
Observational - NUP98/JARID1A as a Recurrent Aberration in Pediatric Acute Megakaryoblastic Leukemia
Status: Enrolling
Updated: 5/17/2016
Children's Oncology Group
mi
from
Monrovia, CA
Click here to add this to my saved trials
Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia
Genetic Predictors of AML Treatment Response
Status: Enrolling
Updated:  5/17/2016
Children's Oncology Group
mi
from
Philadelphia, PA
Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia
Genetic Predictors of AML Treatment Response
Status: Enrolling
Updated: 5/17/2016
Children's Oncology Group
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia
Molecular Taxonomy of Pediatric Cancer
Status: Enrolling
Updated:  5/17/2016
Children's Oncology Group
mi
from
Arcadia, CA
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia
Molecular Taxonomy of Pediatric Cancer
Status: Enrolling
Updated: 5/17/2016
Children's Oncology Group
mi
from
Arcadia, CA
Click here to add this to my saved trials
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
A Phase I Dose Escalation Study of Lenalidomide (Revlimid) in Combination With Fludarabine-Rituximab (Rituxan) for Previously Untreated CLL/SLL
Status: Enrolling
Updated:  5/26/2016
Massachusetts General Hospital
mi
from
Boston, MA
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
A Phase I Dose Escalation Study of Lenalidomide (Revlimid) in Combination With Fludarabine-Rituximab (Rituxan) for Previously Untreated CLL/SLL
Status: Enrolling
Updated: 5/26/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
A Phase I Dose Escalation Study of Lenalidomide (Revlimid) in Combination With Fludarabine-Rituximab (Rituxan) for Previously Untreated CLL/SLL
Status: Enrolling
Updated:  5/26/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
A Phase I Dose Escalation Study of Lenalidomide (Revlimid) in Combination With Fludarabine-Rituximab (Rituxan) for Previously Untreated CLL/SLL
Status: Enrolling
Updated: 5/26/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
Pacific Cancer Care
mi
from
Monterey, CA
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
Pacific Cancer Care
mi
from
Monterey, CA
Click here to add this to my saved trials
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
Maine Center for Cancer Medicine
mi
from
Scarborough, ME
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
Maine Center for Cancer Medicine
mi
from
Scarborough, ME
Click here to add this to my saved trials
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
Massachusetts General Hospital
mi
from
Boston, MA
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
The West Clinic, PC
mi
from
Southaven, MS
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
The West Clinic, PC
mi
from
Southaven, MS
Click here to add this to my saved trials
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
New York Oncology Hematology PC
mi
from
Albany, NY
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
New York Oncology Hematology PC
mi
from
Albany, NY
Click here to add this to my saved trials
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
New York Oncology, Hematology, P.C.
mi
from
Hudson, NY
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
New York Oncology, Hematology, P.C.
mi
from
Hudson, NY
Click here to add this to my saved trials
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
The West Clinic, PC
mi
from
Memphis, TN
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
Moffitt Cancer Center
mi
from
Tampa, FL
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Comprehensive Frailty Assessment
Comprehensive Frailty Assessment
Status: Enrolling
Updated:  6/1/2016
Ohio State University Hospital East
mi
from
Columbus, OH
Comprehensive Frailty Assessment
Comprehensive Frailty Assessment
Status: Enrolling
Updated: 6/1/2016
Ohio State University Hospital East
mi
from
Columbus, OH
Click here to add this to my saved trials
Comprehensive Frailty Assessment
Comprehensive Frailty Assessment
Status: Enrolling
Updated:  6/1/2016
Ohio State University
mi
from
Columbus, OH
Comprehensive Frailty Assessment
Comprehensive Frailty Assessment
Status: Enrolling
Updated: 6/1/2016
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
Immunotherapy for Autologous/Syngeneic Peripheral Blood Stem Cell (PBSC) Transplant Patients as Treatment for Advanced Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
Immunotherapy for Autologous/Syngeneic Peripheral Blood Stem Cell (PBSC) Transplant Patients as Treatment for Advanced Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors
Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors
Status: Enrolling
Updated:  6/6/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors
Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors
Status: Enrolling
Updated: 6/6/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation
Non-Myeloablative Conditioning With Allogeneic Peripheral Blood Progenitor Cell Transplantation Followed by Prophylactic Activated Donor Lymphocyte Infusion (DLI) for the Treatment of High Risk Acute Leukemia/MDS
Status: Enrolling
Updated:  6/7/2016
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation
Non-Myeloablative Conditioning With Allogeneic Peripheral Blood Progenitor Cell Transplantation Followed by Prophylactic Activated Donor Lymphocyte Infusion (DLI) for the Treatment of High Risk Acute Leukemia/MDS
Status: Enrolling
Updated: 6/7/2016
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials